Ophthalmic Business News

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are live at OCTANe OTF with Mark Leahey, Brent Saunders, Yari Mitchell and Robert Dempsey, discussing their experiences and influence across the ophthalmic space.

Reproxalap for the treatment of allergic conjunctivitis achieved the primary and secondary endpoints in the phase 3 INVIGORATE-2 clinical trial, according to a press release from Aldeyra Therapeutics.

Patient dosing is underway in a phase 1b/2 clinical trial of Restoret for the treatment of diabetic macular edema and neovascular age-related macular degeneration, according to a press release from EyeBio.

NEWPORT BEACH, Calif. — In this Healio Video Perspective from Octane’s Ophthalmology Tech Forum, David E.I. Pyott, CBE, discusses how the meeting has evolved as a center for innovation across the ophthalmic industry.

Beacon Therapeutics has launched with the goal of developing a new generation of gene therapies for a range of retinal diseases, according to a press release.

Many investors have recently been asking their advisors, “Is a recession coming?” This question is often on the minds of investors because the financial media repeatedly brings up the topic.

KIAWAH ISLAND, S.C. — In this Healio Video Perspective from Kiawah Eye, Susan Benton and Darrell E. White, MD, provide an overview of the Preservative Freedom Coalition, which was recently launched by Thea Pharma.

EyePoint Pharmaceuticals completed enrollment in the phase 2 PAVIA clinical trial to assess EYP-1901 for the treatment of moderate to severe nonproliferative diabetic retinopathy, according to a press release.

KIAWAH ISLAND, S.C. — In this Healio Video Perspective from Kiawah Eye, Maggie Jeffries, MD, shares why Iheezo is a reliable ocular surface anesthetic option and gives tips on how to use it.

Glaukos completed enrollment in the second phase 3 confirmatory pivotal trial for Epioxa, its epi-on corneal cross-linking therapy, according to a press release.